At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 22 enrolled
Drug / intervention
MCI-186drug
Likely dose
MCI-186 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
In Brief
A Phase 1 clinical trial evaluating MCI-186 for Hepatic Impairment and Healthy. Completed, enrolled 22 participants across 2 sites.
Detailed Summary
To assess the pharmacokinetics of MCI-186 after a single intravenous infusion of 30mg/hour in subjects with mild or moderate Hepatic impairment compared to subjects with normal hepatic function
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Impairment, Healthy
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedSep 2017
Primary CompletionJul 2018
Study CompletionJul 2018
TodayJul 2026
First PostedSep 20, 2017
Enrollment StartNov 16, 2016
Primary CompletionJul 20, 2018
Study CompletionJul 24, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.8 years ago
Interventions
MCI-186drug
30 mg of edaravone will be administered intravenously over 60 minutes